Drug development services supplier CatSci has acquired its UK compatriot Reach Separations. No financial details were disclosed but the company said that this deal was supported by Keensight Capital, a private equity manager dedicated to pan-European growth buyout investments. The whole of the Reach Separations will transfer and the companies will be fully integrated.

French-based CDMO Novasep has announced two sales. Henagen, its Belgium-based viral vectors operation, has been sold to Thermo Fisher Scientific for about €725 million, while, in a much smaller deal, it also intends to sell its chromatography equipment division to Sartorius Stedim Biotech.